Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential...
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, Traws, the Company) today announced it has granted equity awards to new employees who joined Traws in...
Onconova Therapeutics Rigosertib Poster Selected for AACR 2024
Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
Onconova Therapeutics™ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i™s
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics™ ASH Poster To Focus on Narazaciclib in MCL
Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D